long intergenic non-protein coding RNA 2292Genealiases: []
Q-omics provides the consensus-scored LINC02292 profile across patient tissues and cancer cell-line models. LINC02292 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC02292 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, LINC02292 RNA expression shows 10,685 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where LINC02292 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02292 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02292 survival associations across molecular data types. LINC02292 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02292 RNA expression–survival associations across cancer types. High LINC02292 expression shows unfavorable associations in THCA and CHOL, but favorable associations in KIRC, LAML, SKCM and KICH. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC02292 RNA expression.
This table summarizes LINC02292 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02292. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02292 shows lower tumor expression in KIRC, COAD, KIRP, KICH and THCA and higher tumor expression in LIHC. The KIRC box plot shows higher LINC02292 RNA expression in normal versus tumor tissue (log2 FC = −0.257, t-test p < 0.001).
This table shows molecular features associated with LINC02292 in patient tissues and cancer cell lines. In patient samples, LINC02292 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
